AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glympse Bio Names Tracey Dawson as Chief Commercial Officer and Head of Strategy

November 4, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 4, 2019--

Glympse Bio, Inc., a life science company developing a non-invasive technology to directly query disease activity inside the body, today announced the expansion of its leadership team with the appointment of Tracey Dawson, Ph.D., as Chief Commercial Officer and Head of Strategy. Dr. Dawson, whose expertise includes commercial and business development for franchise therapies, as well as lifecycle and alliance management, will help advance the company’s growing development pipeline.

“We are pleased to have Tracey join our leadership team at such an important time,” said Caroline J Loew, President and CEO of Glympse. “Over her career in biopharma, Tracey has been known for her commitment to delivering high value results by focusing on an integrated approach to product development and commercialization. With our deep pipeline and growing portfolio of commercial partnerships, we are well positioned to benefit from her expertise.”

Dr. Dawson commented, “I’m delighted to be joining Glympse at such a pivotal time. Glympse’s technology is uniquely positioned to impact every aspect of a patient’s journey - from disease detection, through treatment response, and back to health - and I’m pleased to be part of the team that will make this a reality.”

Dawson joins Glympse from Biogen, where she was Vice President of Global Product Development and Commercialization for the Multiple Sclerosis (MS) Franchise. In that role, she redefined their MS Therapeutic Area Strategy initiating multiple new development programs and helping build a new product development operating model. Previously she was at Shire as Group Vice President and Head US Genetic Diseases Franchise, and before that, she spent 6 years at Genentech in roles of increasing responsibility in marketing, franchise management, new product planning and lifecycle management. She began her career in the UK at Eli Lilly. Dawson trained as a research chemist and holds a Ph.D. in Physical Organic Chemistry from the University of Hull, UK.

ABOUT GLYMPSE BIO, INC.
Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body. The Company’s proprietary synthetic biomarkers - biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence - are perfectly tunable to any disease, and offer earlier measures of response to disease and treatment. By integrating real-time biological activity with sophisticated machine learning and artificial intelligence, Glympse Inside™ is a pan-disease product engine that aims to transform disease monitoring and treatment response. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005061/en/

CONTACT: Beth Kurth

Conway Communications

617-584-9650

bkurth@conwaycommsir.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH OTHER HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY

SOURCE: Glympse Bio, Inc.

Copyright Business Wire 2019.

PUB: 11/04/2019 10:30 AM/DISC: 11/04/2019 10:30 AM

http://www.businesswire.com/news/home/20191104005061/en